



Mestinon[®] (pyridostigmine) – First-time generic

- On March 11, 2019, [Novitium Pharma launched](#) an [AA-rated](#) generic version of Bausch Health's [Mestinon \(pyridostigmine\)](#) oral solution.
- Mestinon is approved for the treatment of myasthenia gravis.
- Pyridostigmine is also available generically as a [tablet](#), an [extended-release tablet](#), and brand intravenous solution ([Regonol[®]](#)).
 - The tablet and extended-release tablet carry the same indication as the oral solution.
 - Regonol is indicated as a reversal agent or antagonist to the neuromuscular blocking effects of nondepolarizing muscle relaxants.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.